Binge eating disorder (BED) BED is the most common eating disorder in people with obesity, affecting up to 30% of patients in bariatric and weight management settings [130]
ROS participate in a wide range of important signaling processes including growth, development, the cell cycle, acclimation to stress and programmed cell death 1,2,3,4
thus, it can circumvent the degradation of dipeptidyl peptidase-4 (DPP-4) and has a prolonged intravenous half-life of 30 min and a 23 h half-life after subcutaneous administration
Patient-centric considerations are equally important, with a growing demand for treatments that are easier to use , whether that means less frequent dosing, oral options, or alternatives to injections